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Statement of Translational Relevance 
 
Tamoxifen and chemotherapy are key treatments for breast cancer patients. 
Tamoxifen, an oestrogen antagonist, is a non-steroidal that acts as a selective 
oestrogen receptor modulator (SERM). It competitively inhibits the interaction of 
oestrogen with the oestrogen receptor, blocking the effects of E2 and inhibiting 
receptor activity. Chemotherapy uses cytotoxic drugs to kill cancer cells, by 
preventing them from multiplying, invading and metastasing. Despite the extensive 
use of both treatments, failure to respond to them is a major clinical problem and this 
is the cause of significant morbidity and mortality. To overcome this and to improve 
patients’ treatment options, we need to understand the mechanisms regulating the 
development of resistance. This study suggests that activation of the Ras pathway 
predicts for poor outcome on tamoxifen but not chemotherapy, and identifies 
pRaf(ser338) as a potential marker of resistance to ER-targeted therapy. In addition, it 
suggests that expression of pRaf(ser338) could identify patients for whom tamoxifen 
alone is insufficient adjuvant systemic therapy, but for whom the addition of 
chemotherapy may be of benefit.  
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Abstract 
Purpose: Expression and activation of the Ras/Raf-1/MAPK pathway plays an 
important role in the development and progression of cancer, and may influence 
response to treatments such as tamoxifen and chemotherapy. In this study we 
investigated whether expression and activation of the key components of this pathway 
influenced clinical outcome, to test the hypothesis that activation of the MAPK 
pathway drives resistance to tamoxifen and chemotherapy in women with breast 
cancer.  
Experimental Design: Breast tumours from patients at Glasgow Royal Infirmary and 
others treated within the BR9601 trial were analysed for expression of the three Ras 
isoforms, total Raf-1, active and inactive forms of Raf-1 (pRaf(ser338) and 
pRaf(ser259), respectively), MAPK and phospho-MAPK using an 
immunohistochemical approach. Analyses were performed with respect to disease 
free-survival and overall survival.  
Results: Expression and activation of the Ras pathway was associated with loss of 
benefit from treatment with tamoxifen but not chemotherapy. Overexpression of 
pRaf(ser338) was associated with shortened disease-free and overall survival time in 
univariate analyses. Multivariate analysis suggested pRaf(ser338) was independent of 
known prognostic markers in predicting outcome following tamoxifen treatment 
(p=0.03). 
Conclusion: This study suggests that activation of the Ras pathway predicts for poor 
outcome on tamoxifen but not chemotherapy, and identifies pRaf(ser338) as a 
potential marker of resistance to ER-targeted therapy. In addition, it suggests that 
expression of pRaf(ser338) could identify patients for whom tamoxifen alone is 
insufficient adjuvant systemic therapy, but for whom the addition of chemotherapy 
may be of benefit. 
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Introduction 
The Ras/Raf-1/MAPK pathway controls multiple cellular processes, including 
proliferation, differentiation, senescence and apoptosis (1). Activation follows 
membrane tyrosine kinase receptors (EGFR, HER2-4) binding appropriate ligands, 
dimerising and undergoing autophosphorylation (2,3). This activates Ras, which 
translocates to the plasma membrane and promotes Raf-1 phosphorylation and 
activation (4-13). Raf-1 phosphorylates and activates MEK, which activates MAPK, a 
serine/threonine kinase responsible for phosphorylating and activating substrates, 
including c-fos and c-myc, which regulate proliferation (14,15). MAPK also 
phosphorylates and activates the oestrogen receptor (ERα) (16-19). 
Expression and activation of the Ras/Raf-1/MAPK pathway plays an 
important role in the development and progression of cancer, and may additionally 
influence response to treatments targeted against ERα and proliferation. 
Chemotherapy and endocrine therapy are thought to target proliferating cells, and 
whilst it remains unclear if highly proliferating tumours are more sensitive to 
treatment, we hypothesised that activation of this pathway would be an indicator of 
responsiveness to endocrine and cytotoxic therapies. 
 The majority of chemotherapeutic agents are thought to function most 
effectively against proliferating tumour cells in growth phase. Recently the National 
Epirubicin Adjuvant Trial (NEAT) and BR9601 trial confirmed that the anthracycline, 
epirubicin, plus CMF, is superior to CMF alone as adjuvant treatment for patients 
with early breast cancer (22). Since these agents are more effective against rapidly 
cycling cells (23), it is feasible that tumours with low proliferative indices may be less 
sensitive to these therapeutic agents. However, proliferative indices alone are poor 
predictors of chemotherapeutic response (24).  
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Several studies suggest that the Ras/Raf-1/MAPK pathway is linked to 
response to anthracycline treatment. In vitro Raf-1 (25,26) and MAPK (27) 
expression are associated with increased proliferation and anthracycline resistance. 
Conversely, increased MAPK activation has been linked to enhanced apoptosis and 
anthracycline sensitivity (28). The role of the Ras pathway in determining 
chemosensitivity therefore requires further investigation. 
Activation of Ras/Raf-1/MAPK is also linked to tamoxifen resistance through 
phosphorylation of ERα. The classic “genomic” action of ERα requires ligand 
binding, which induces phosphorylation, dissociation from heat shock proteins 
(Hsps), conformational changes, homodimerisation and nuclear translocation. Nuclear 
ERα binds to ERE sequences in the promoter region of oestogen regulated genes (29) 
and recruits co-activators, co-repressors and transcription machinery (16,30,31). ERα 
can, however, be activated in a ligand-independent manner via signalling pathways. 
The Ras/Raf-1/MAPK pathway phosphorylates Serine 118, within the AF-1 domain 
of the receptor, (16,18,19,32) resulting in its activation and transcription of oestrogen-
regulated genes and cell proliferation. Consequently, the Ras pathway is thought to 
increase ERα sensitivity to low concentrations of oestrogen, resulting in tamoxifen 
resistance (33-35). Tamoxifen-resistant cells have been shown to have increased 
levels of activated MAPK, phosphorylated ERα and transcription of oestrogen-
regulated genes (36,37). 
This study investigated whether expression and activation of the key 
components of the Ras/Raf-1/MAPK pathway influenced clinical outcome, to test the 
hypothesis that activation of the pathway drives resistance to tamoxifen and 
chemotherapy in clinical breast cancer. In order to achieve this two different patient 
groups were used, a tamoxifen treated and a chemotherapy treated cohort. The study 
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population included ER+ve patients who received tamoxifen treatment alone and in 
combination with chemotherapy, and patients from the Scottish BR9601 trial who 
received either CMF or sequential epirubicin followed by CMF.  
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Materials & Methods  
Patient Cohorts 
 
Two patient cohorts were studied, after obtaining ethical approval for each study 
separately. The first comprised 402 patients with ERα positive tumours who were 
treated at Glasgow Royal Infirmary between 1980-1999 (Steroid Resistant Tumour 
Bank – STB). These patients received adjuvant tamoxifen for a median of 5 years 
(range 0.6-18 years) and follow-up data was available for a median of 6.45 years 
(range 0.64-18.42 years). In addition, 99 (24.8%) of these patients received adjuvant 
chemotherapy and 110 (27.5%) received adjuvant radiotherapy. ERα status was 
defined as previously described (38). Clinical/pathological characteristics for these 
patients are shown in Table 1. In this study there were 74 breast cancer specific deaths 
and 100 breast cancer relapses, 78 of which occurred during tamoxifen treatment.  
An additional 318 patients were studied, from the BR9601 adjuvant 
chemotherapy trial designed to test the possible benefit of 4 cycles of epirubicin 
followed by 4 cycles of CMF over 8 cycles of CMF chemotherapy in women with 
early breast cancer. There was a median follow up of 4.95 years (range 0.27-8.52 
years), with 84 breast cancer related deaths and 111 breast cancer recurrences (both 
local and distant). Clinical/pathological characteristics are again shown in Table 1.  
 
 Antibodies 
Ras protein expression was investigated using three isoform specific antibodies: H-
Ras (IgG1 Ab, F235, Santa Cruz, CA, USA); K-Ras (Sigma, Dorset, UK) and N-Ras 
(IgG1 Ab, F155, Santa Cruz). Raf-1 protein expression was measured using a Raf-1 
antibody (IgG1 Ab, E-10, Santa Cruz) and two phospho-specific antibodies 
recognising active and inactive Raf-1: phospho-Raf(ser338) (Upstate, CA, USA) and 
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phospho-Raf(ser259) (Cell Signalling Technology, MA, USA; CST), respectively. 
MAPK expression was investigated using a p44/42MAPK antibody (CST) and a 
phospho-specific p44/42 MAPK(Thr202/Tyr204) antibody (CST). All Ras antibodies 
were used at a concentration of 20µg/ml; the Raf-1 antibody was used at 5µg/ml, the 
phospho-Raf-1 antibodies at 4µg/ml, and both MAPK antibodies at 0.5µg/ml in 
antibody diluent (DAKO, Glostrup, Denmark) for immunohistochemistry. All 
antibodies were used to investigate protein expression in the STB study but only 
pRaf(ser259), pRaf(ser338), MAPK and pMAPK antibodies were used in the BR9601 
study. The specificity of all antibodies was confirmed by western blotting. 
Western Blotting  
Proteins from unstimulated and 10nM Heregulin (HRG) stimulated MCF-7 and 
MDA-MB-453 cells were resolved by 10% SDS-PAGE at 40mA for 1 hour and 
transferred to PVDF membrane overnight at 10V. The membrane was treated with 5% 
BSA in TTBS (Tris Buffered Saline-Tween) for 1 hour and incubated with primary 
antibody (H-Ras, N-Ras, Raf-1, pRaf(ser338) = 0.4µg/ml, K-Ras, pRaf(ser259), 
MAPK, pMAPK = 0.2µg/ml) overnight at 4oC. Membranes were incubated in 
appropriate secondary antibody for 1 hour, anti-mouse IgG (CST, 1:10000) for H-Ras, 
K-Ras, N-Ras and Raf-1 and anti-Rabbit IgG (CST, 1:5000) for pRaf(ser259), 
pRaf(ser338), MAPK and pMAPK, and visualised using chemiluminescence 
(Western blotting detection reagent; Amersham Biosciences, Buckinghamshire, UK).   
TMA Construction 
Tissue microarrays (TMA) were constructed for 402 ERα positive STB tumours and 
the 318 BR9601 breast tumours (39).  TMA construction allows rapid tumour 
processing under standardised conditions and has been extensively validated in breast 
cancer. Up to 100-200 (0.6 diameter) individual tumour cores were placed into a 
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single recipient block enabling simultaneous multiple tumour analysis. A consultant 
breast pathologist was responsible for marking tumour areas on haematoxylin and 
eosin stained tumour slides prior to coring.  To account for tumour heterogeneity, 3* 
0.6 mm cores were removed from the marked areas in each tumour block and 
transferred to recipient paraffin blocks to form the TMA. 
Immunohistochemistry 
IHC for H-Ras, N-Ras and Raf-1 was performed as previously described (40). For 
pRaf(ser338) and K-Ras, antigen retrieval was performed by heating under pressure in 
TE buffer (1mM EDTA, 5mM Tris, pH 8.0) for five minutes in a microwave. For 
pRaf(ser259), p44/42 MAPK and phospho-p44/42 MAPK, slides were incubated in 
10mM Citrate Buffer at 96oC for twenty minutes. Endogenous peroxide was blocked 
by incubation in 0.3% hydrogen peroxide (H2O2) (except for K-Ras, where 3% H2O2 
was used). Blocking was performed using 1.5% normal horse serum (Vector 
Laboratories, CA, USA; H-Ras, N-Ras, Raf-1, p44/42 MAPK and phospho-p44/42 
MAPK) or Casein solution (Vector Laboratories; K-Ras, pRaf(ser259) and 
pRaf(ser338)). Antibody incubations were performed overnight at 4oC, with the 
exception of phospho-p44/42 MAPK (six hours at room temperature). In each run a 
negative isotype matched and a positive control, using breast tumour tissue known to 
express the protein of interest, were included. Signal was visualised using Envision 
(DAKO) and 3,3’-diaminobenzidine (DAB, Vector Laboratories). For the K-Ras 
antibody, the Super Sensitive Non-Biotin HRP Detection System (BioGenex, CA, 
USA) was used.  
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Histoscore Method 
Two observers (LM & TK) trained by a pathologist, independently scored tumour 
cores, as selected by a pathologist, using a weighted histoscore method(41,42). The 
intensity of cytoplasmic and nuclear staining was categorised as negative (0), weak 
(1), moderate (2) and strong (3) and the percentage of tumour cells within each 
category estimated. The histoscore was calculated using the following formula: 
Histoscore = 0 x % negative tumour cells + 1 x % weakly stained tumour cells + 2 x 
% moderately stained tumour cells + 3 x % tumour cells stained strongly. The 
histoscore ranged from a minimum of zero to a maximum of 300. Agreement between 
the two observers was monitored. Cases with discordant results between observers 
were re-evaluated. Agreement between observers was excellent with Interclass 
correlation coefficients (ICCC) scores between 0.74-0.97. 
 
Statistical Analysis 
 
Statistical analysis was performed using the SPSS statistical package (version 9.0 for 
Windows). Correlations between proteins were calculated using the Spearman Rank 
Test. Pearsons chi-square test was used to correlate protein expression with known 
prognostic factors. Kaplan-Meier life-table analysis and Cox’s multiple regression 
(including known prognostic factors tumour size, grade and nodal status) were 
performed to estimate differences in breast cancer related survival, in terms of 
disease-free survival (DFS) and overall survival (OS), using breast cancer recurrences 
and breast-cancer specific deaths as the respective end-points. To establish the relative 
risk of a patient relapsing or dying as a result of either high or low levels of a 
particular protein in their breast tumour, hazard ratio analysis was calculated by Cox’s 
multiple regression using only the protein of interest as a variable. For survival 
analysis and chi-square tests, patients were split into two groups, those that expressed 
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high levels of protein and those that expressed low levels. For all proteins analysed, 
high levels were defined as IHC scores equal to or above the upper quartile value, 
whilst low levels were defined as IHC scores less than the upper quartile value.  A 
value of p<0.05 was deemed statistically significant.  
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Results 
 
Patient cohort & treatment 
Of 402 STB patients, 303 individuals received tamoxifen alone, whilst the remaining 
99 received both tamoxifen and chemotherapy. Survival analysis was performed on 
the entire cohort but also on the subgroup of patients who received only tamoxifen, 
thus addressing the potential confounding effects of both endocrine and chemotherapy 
treatments. Patients from the BR9601 trial were randomly allocated to receive either 
CMF alone or epirubicin followed by CMF. Three hundred and eighty four patients 
were randomised in BR9601 and tissue samples retrieved from 318 cases (84%). One 
hundred and fifty five (49%) patients received treatment with epirubicin followed by 
CMF while the remaining 163 (51%) patients received only CMF. Additionally, 165 
of the BR9601 patients received tamoxifen. A survival analysis of those patients 
whose samples contributed to this sub-study confirmed the statistical advantage of 
Epi-CMF over CMF observed in the main BR9601 and NEAT studies (43)  (data not 
shown). 
 
Protein Expression  
H-, K- and N-Ras and Raf-1 expression was investigated in the STB cohort, whilst the 
inactivated and activated form of Raf-1, pRaf(ser259) and pRaf(ser338) respectively, 
and MAPK and pMAPK, were analysed in both the STB and BR9601 cohort of 
patients. With the exception of pRaf(ser259), which was localised primarily to the 
cytoplasm, all proteins were expressed in both the cytoplasm and nuclei of tumour 
cells (Figure 1, Table 2).  Despite the high frequency of patients expressing both 
cytoplasmic and nuclear H- K- and N-Ras, there was no significant relationship 
between the expression levels of Ras in the two locations.  However, a strong positive 
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correlation was evident between the cytoplasmic and nuclear localisation of Raf-1, 
pRaf(ser338), MAPK and pMAPK. 
 
Activation of the Ras/Raf-1/MAPK pathway in breast tumours  
Tumours from the STB and NEAT cohorts with elevated activated Raf, pRaf(ser338), 
also expressed increased levels of cytoplasmic and nuclear pMAPK (Spearman’s rank 
test; Table 3). In the STB study, overexpression of Ras isoforms was associated with 
increased activated Raf expression; N-Ras was most markedly correlated with pRaf 
(p<0.0005, CC = 0.274, Table 3). 
 
Protein expression and association with known prognostic markers 
In the STB cases nuclear pRaf(ser338) expression was positively correlated with node 
positivity (p=0.009), elevated expression of cytoplasmic pRaf(ser338) was associated 
with increased tumour grade (p=0.001). Cytoplasmic MAPK expression was 
positively associated with tumour grade (p=0.025), size (p=0.002) and nodal status 
(p<0.0005). No correlations were observed between nuclear MAPK and known 
prognostic markers. 
Conversely, in the BR9601 chemotherapy treated patients no significant 
correlations were observed between pRaf(ser338) expression and node positivity, 
tumour size or grade. Increased nuclear MAPK and cytoplasmic pMAPK expression 
was related to lower (grade 1 or 2) grade of tumour (p=0.01 and p=0.0017 
respectively). 
 
 
 
 15
Steroid tumour bank (STB) survival analysis 
Raf-1 activation was associated with shortened disease-free survival (DFS) in the 402 
STB patients. High cytoplasmic pRaf(ser338) expression in tumours  was associated 
with a reduced time to recurrence (p=0.002) (Figure 2a).  Patients with tumours 
expressing increased levels of nuclear pRaf(ser338) also exhibited reduced DFS 
(p=0.006). Hazard ratios (HR) were 1.84 (95% CI 1.24 - 2.75, p=0.0026) and 1.78 
(95% CI 1.17 – 2.71, p=0.007) respectively. (Figure 2b). No association was observed 
between Ras, pRaf(ser259), MAPK or pMAPK and DFS in this series. 
Overall survival (OS) for the 402 patients treated in this series was not 
associated with increased expression of the Ras isoforms, pRaf(ser259), MAPK or 
pMAPK. Patients whose tumours expressed increased levels of cytoplasmic or 
nuclear pRaf(ser338) exhibited a reduced OS following tamoxifen treatment 
(p=0.0229) and (p=0.0006) respectively (Figure 2c,d).  Hazard ratios were 1.74 (95% 
CI 1.07-2.81, p=0.0247) and 2.29 (95% CI 1.41-3.74, p=0.0009) respectively.  
 
BR9601 survival analysis 
Survival analysis revealed no significant association between tumour 
expression of pRaf(ser259), pRaf(ser338), MAPK or pMAPK and risk of breast 
cancer recurrence or death in BR9601 patients receiving chemotherapy (Epi/CMF or 
CMF) either alone or with tamoxifen. 
 
ER positive tamoxifen only treated cases (303 STB cases) survival analysis 
In the 303 STB cases treated only with tamoxifen, patients with tumours 
overexpressing cytoplasmic (p=0.0023, 10.2 years versus 13.3 years) or nuclear 
pRaf(ser338) (p=0.002, 10.3 years versus 12.8 years) had worse DFS (Figure 3a,b). 
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The relative risks for relapse associated with increased expression of cytoplasmic or 
nuclear pRaf(ser338) were 2.02 (95% CI 1.27-3.21, p=0.0028) and 2.08 (95% CI 
1.29-3.33, p=0.0025) respectively. Increased cytoplasmic or nuclear pMAPK 
expression was associated with a shorter DFS in patients treated with tamoxifen alone 
(p=0.01, 8.5 years versus 12.9 years, Figure 3c, HR 2.04) and (p=0.04, 11.4 years 
versus 12.5 years, HR1.61) respectively. Multivariate Cox-Regression analysis 
revealed that only nuclear pRaf(ser338) expression was independent of tumour size, 
grade or nodal status in influencing relapse (p=0.03, Table 4). 
Activation of Raf-1 was also linked to a poor outcome in this sub-set of 
patients. Elevated cytoplasmic or nuclear pRaf(ser338) expression was associated 
with shortened OS time (p=0.015, 13.6 years versus 15.06 years) and (p=0.0008, 11.8 
years versus 15.72 years) respectively (Figure 4a,b). Increased expression of 
cytoplasmic or nuclear pRaf(ser338) raised the risk of death by 1.96 (95% CI 1.13-
3.42, p=0.017) and 2.52 (95% CI 1.44-4.41, p=0.0012) times respectively.  
Increased expression of MAPK and pMAPK were also associated with a 
significant reduction in OS time in patients treated only with tamoxifen. Patients 
whose tumours expressed high levels of cytoplasmic and nuclear MAPK were more 
likely to die sooner than those with low levels (p=0.033, 13.2 years versus 15.6 years) 
and (p=0.039, 13.11 years versus 15.60 years) respectively (Figure 4c,d).  The relative 
risk for these patients was 1.84 (95% CI 1.04-3.26) and 1.78 (95 CI% 1.02-31.2) for 
cytoplasmic and nuclear MAPK respectively. Likewise patients with increased 
tumour levels of nuclear pMAPK exhibited a shortened OS time (p=0.0336, 13.50 
years versus 16.10 years) (Figure 4e). Increased expression of nuclear pMAPK 
increased the risk of death in patients treated with tamoxifen by 1.83 (95% CI 1.04-
3.24) times. Multivariate analysis excluded pRaf(ser338), MAPK or pMAPK as being 
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independent of known predictive factors (tumour size, grade and nodal status) for 
overall survival. 
 
ER positive tamoxifen and chemotherapy treated cases (STB and BR9601) 
For the 264 ER positive patients in the combined STB and BR9601 populations who 
received both tamoxifen and chemotherapy there was no significant association 
between tumour expression of pRaf(ser259), pRaf(ser338), MAPK, or pMAPK and 
shortened DFS or OS time (data not shown).  
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Discussion 
This study demonstrates that the Ras/Raf-1/MAPK pathway is activated in clinical 
breast tumours and suggests that activation is associated with poor outcome, 
particularly in patients treated with tamoxifen alone.  
Analysis of 402 cases treated with tamoxifen suggested that poor outcome was 
associated with the expression and activation of the Ras cascade, in particular 
activation of Raf-1 (Figure 1). In contrast, activation of this pathway was not 
associated with outcome in a chemotherapy and tamoxifen treated population from 
the BR9601 study. This contrasting result from two populations of breast cancer 
patients, analysed within the same laboratory, but with differing treatment regimens, 
led us to hypothesise that activation of Raf-1 may be associated with poor outcome in 
ERα positive patients treated with adjuvant tamoxifen. We therefore performed two 
exploratory analyses, one on the 303 ERα positive cases from the STB cohort which 
received only tamoxifen and on the 264 ERα positive cases (99 from the STB and 165 
from the BR9601 study) who received chemotherapy and tamoxifen.  
Survival analysis demonstrated that increased expression of cytoplasmic and 
nuclear pRaf(ser338) was associated with increased risk of relapse and death in the 
303 tamoxifen only treated patients and on multivariate analysis nuclear pRaf(ser338) 
expression was independent of nodal status, tumour size and grade (p=0.031). In 
addition, elevated levels of cytoplasmic and nuclear pMAPK were associated with an 
increased risk of recurrence in this patient cohort.  Conversely, in the 264 ERα 
positive patients treated with both chemotherapy and tamoxifen, no association with 
phosphorylated Raf-1 or MAPK was observed with patient outcome measures.  
These results suggest that increased Raf-1/MAPK phosphorylation, or 
activation is associated with early relapse on adjuvant tamoxifen and that nuclear 
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pRaf(ser338) is a candidate for identifying ERα positive patients at risk of relapse if 
treated with tamoxifen alone. We cannot at present, rule out the possibility that 
pRaf(ser338) functions as a prognostic marker, as opposed to predictive marker, since 
all cases analysed received adjuvant therapy, however it appears to function at least 
additionally as a predictive factor for improved benefit from chemotherapy. In the 99 
STB patients who received both adjuvant tamoxifen and chemotherapy, it seemed that 
the addition of chemotherapy increased the time to relapse in those patients 
expressing high levels of pRaf(ser338). Interestingly, pRaf(ser338) was not an 
independent predictor of tamoxifen resistance when the 303 tamoxifen only and 99 
tamoxifen and chemotherapy treated patients were combined. This suggests that 
chemotherapy partially overrides the negative effects of increased expression of 
nuclear pRaf(ser338). Increased tumour levels of pRaf(Ser338) are perhaps indicative 
of decreased benefits from tamoxifen but enhanced response to chemotherapy. This 
supports previous findings that increased expression of Raf-1 in cell lines makes them 
more responsive to chemotherapeutic agents (44). To confirm this hypothesis, ideally 
analysis of an untreated patient cohort would be undertaken to address any potential 
prognostic role and to determine if pRaf(ser338)is also a predictive marker in the 
context of benefit associated with tamoxifen therapy. 
Raf-1 is a serine-threonine kinase that plays a role in cell proliferation, 
differentiation and apoptosis, and is prominent in controlling tumour angiogenesis and 
metastasis (45,46). We show that increased Raf-1 activity in tumours was related to 
poorly differentiated tumours (high grade) and tumour spread (node positivity). A 
recent study demonstrated that targeting Raf-1 inhibits tumour growth and that this 
represents an important therapeutic strategy (47).  
 20
The ligand-independent phosphorylation of ERα at serine 118 by MAPK is 
believed to be a major contributor to the development of tamoxifen resistance and this 
relationship between the Ras/Raf-1/MAPK pathway and ERα has been well 
documented.  It is hypothesised that phosphorylation of ERα contributes to tamoxifen 
resistance by promoting tumour growth in the presence of low levels of oestrogen 
(48,49). However in the current study nuclear pRaf(ser338) appears to be dominant 
over MAPK, which implies that whilst MAPK driven phosphorylation of ERα may be 
important, it is not the only contributing factor in the development of tamoxifen 
resistance. It also suggests that the mechanism by which nuclear pRaf(ser338) 
influences tamoxifen resistance is independent of MAPK.  
In summary, this study demonstrates that expression and activation of the 
Ras/Raf-1/MAPK pathway in breast tumours is associated with increased risk of 
relapse and death with tamoxifen treatment but not when chemotherapy is also given 
to ERα positive cases. These results suggest that activated Raf-1 is a potential 
predictive marker for identifying patients who are least likely to benefit from 
tamoxifen and for whom additional therapy may be required.  
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STB  
Patients 
 BR9601 
Patients 
 
 
Number/total % Number/Total % 
1 99/391 25.32 20/305   6.55 
2 193/391 49.36 100/305 32.79 
3 99/391 25.32 185/305 60.66 Grade 
unknown 11  13  
0 193/369 52.3 43/313 13.74 
1-3 107/369 29.0 176/313 56.23 
4+ 69/369 18.7 94/313 30.03 
Nodal 
status 
unknown 33  5  
T1 (<20mm) 154/380 40.53 94/308 30.52 
T2 (20-50mm) 204/380 53.68 203/308 65.91 
T3 (>50mm) 22/380 5.79 11/308 3.57 Size 
unknown 22    
<3.5 128/344 37.21 65/311 20.9 
3.5-4.5  106/344 30.81 148/311 47.59 
4.5+ 110/344 31.98 98/311 12.86 NPI 
Missing 58   7  
<50 years 73/401 18.2 90/318 28.3 
Age >50 years 
Missing 
328/401 
1 
81.8 228/318 71.7 
+ve 402/402 100.0 174/278 62.59 
-ve   104/278 37.41 ER Status 
Unknown   40  
Epi & CMF n/a  155/318 48.74 Treatment CMF Alone n/a  163/318 51.26 
 
Table 1: Patient clinical and pathological variables 
Grade = Bloom and Richardson grade. Nodal status = number of positive nodes.  
NPI = Nottingham Prognostic Index = grade+nodal status+0.02*size in mm. 
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Protein Cytoplasmic Expression Median Histoscore  (IQ Range) 
Nuclear Expression 
Median Histoscore (IQ Range) 
H-Ras 125 (90-157) 40 (20-70) 
K-Ras 53 (27-85) 23 (8-50) 
N-Ras 147 (113-180) 100 (80-117) 
Raf-1 123 (83-153) 108 (91-123) 
pRaf(ser259) 71 (30-120) 0 (0-3) 
pRaf(ser338) 157 (120-185) 137 (113-160) 
MAPK 110 (68-147) 75 (50-100) 
pMAPK 60 (25-95) 68 (40-95) 
 
Table 2: Protein Expression in Breast Tumours 
Table 2 shows the median histoscore and interquartile range (IQ) for protein 
expression in the cytoplasm and nuclei of breast tumour cells. 
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Table 3: Correlations between Ras and Raf 
Spearman Rank Tests were performed to analyse the relationship between 
overexpression of the three Ras isoforms and phosphorylation of Raf at serine 259 
and serine 338 in the cytoplasm and nuclei. Only cytoplasmic pRaf(ser259) was 
analysed because only very low levels of nuclear pRaf(ser259) were detected. R2 = 
correlation coefficient. p values < 0.05 were deemed statistically significant. ns = non-
significant. 
 
pRaf(ser338)  
Cytoplasmic Nuclear 
Cyto R
2
 = 0.130 
p=0.015 ns H-Ras 
Nuc R
2
= -0.163 
p=0.002 ns 
Cyto R
2
 = 0.226 
p<0.0005 ns K-Ras 
Nuc ns R
2
 = 0.143 
p = 0.007 
Cyto R
2
 = 0.274 
p<0.0005 ns N-Ras 
Nuc R
2
 =-0.217 
p<0.0005 ns 
 
pMAPK Cyto 
R2 = 0.240 
p<0.0005 
R2 = 0.246 
p<0.0005 
 Nuc R
2
 = 0.217 
p<0.0005 
R2 = 0.334 
p<0.0005 
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Factor Hazard Ratio p-value 
Nodal Status  
(0, 1-3, 4+) 2.01 (1.41 – 2.87) p=0.0002 
Tumour Grade 
(1, 2, 3) 1.47 (0.99 – 2.20) p=0.0552 
Tumour Size 
(T1 <20mm, T2 20-
50mm, T3 >50mm) 
2.23 (1.31 – 3.81) p=0.0027 
Nuclear pRaf(ser338) 
(IHC score < 160, IHC 
score >160) 
1.94 (1.09 – 3.45) p=0.0307 
 
Table 4: Factors that independently influence disease-free survival time of 
patients treated only with tamoxifen 
Cox-Regression multivariate analysis revealed that nuclear pRaf(Ser338) expression 
was independent of known prognostic markers; nodal status, tumour size and grade, in 
influencing disease-free survival time in patients treated only with tamoxifen. p-
values < 0.05 were deemed statistically significant. Hazard ratio = relative risk 
associated with development of tamoxifen resistance (95% CI). 
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Figure Legends 
Figure 1: Immunohistochemical Staining of Breast Tumour Tissue 
 
Immunohistochemistry pictures of breast tumour tissue stained with (a),H-Ras (b)K-
Ras, (c) N-Ras, (d)Raf-1, (e) pRaf(ser259), (f) pRaf(ser338), (g )p44/42MAPK and (h) 
phospho-p44/42MAPK  antibodies. For all antibodies the proteins are detected in 
both the cytoplasm and the nuclei of tumour cells. 
 
Figure 2: pRaf(ser338) Disease Free & Overall Survival Curves in 402 STB 
patients  
Kaplein Meier survival curves showing disease-free survival (DFS) in patients whose 
tumours express cytoplasmic and nuclear pRaf(ser338). (a) Survival curve showing a 
significant reduction in DFS in patients whose tumours express high levels of 
cytoplasmic pRaf(ser338) (p=0.0022). (b) Survival curve showing a significant 
reduction in DFS in patients whose tumours express high levels of nuclear 
pRaf(ser338) (p=0.0064). (c) Survival curve showing a significant reduction in 
overall survival time in STB patients treated with tamoxifen and chemotherapy, whose 
tumours express high levels of cytoplasmic pRaf(ser338) (p=0.0229). (d) Survival 
curve showing a significant reduction in overall survival time in STB patients treated 
with tamoxifen and chemotherapy, whose tumours express high levels of nuclear 
pRaf(ser338) (p=0.0006). High levels were defined as scores ≥ upper quartile value. 
p values represent log rank testing of the differences in survival. HR=Hazard Ratio 
(95% CI) 
 
Figure 3: Tamoxifen only treated patients disease free survival curves 
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Kaplein Meier survival curves showing disease-free survival in patients treated only 
with tamoxifen whose tumours express pRaf(ser338) and pMAPK. (a) Survival curve 
showing a significant reduction in disease-free survival time in patients whose 
tumours express high levels of cytoplasmic pRaf(ser338) (p=0.0023). (b) Survival 
curve showing a significant reduction in disease survival time in patients whose 
tumours express high levels of nuclear pRaf(ser338) (p=0.0020). (c) Survival curve 
showing a significant reduction in disease-free survival time in patients whose 
tumours express high levels of cytoplasmic pMAPK (p=0.0104). High levels were 
defined as scores ≥ upper quartile value. p values represent log rank testing of the 
differences in survival. HR=Hazard Ratio (95% CI). 
 
Figure 4: Overall survival curves for 303 tamoxifen only treated STB patients 
Kaplein Meier survival curves showing overall survival (OS) in 303 STB patients 
treated only with tamoxifen. (a) Survival curve showing a significant reduction in OS 
time in STB patients whose tumours express high levels of cytoplasmic pRaf(ser338) 
(p=0.0154). (b) Survival curve showing a significant reduction in OS time in STB 
patients, whose tumours express high levels of nuclear pRaf(ser338) (p=0.0008). (c) 
Survival curve showing a significant reduction in OS  time in STB  patients whose 
tumours express high levels of cytoplasmic MAPK (p=0.0331). (d) Survival curve 
showing a significant reduction in OS time in STB patients whose tumours express 
high levels of nuclear MAPK (p=0.0395) (e) Survival curve showing a significant 
reduction in OS time in STB  patients, whose tumours express high levels of nuclear 
pMAPK (p=0.0336).High levels were defined as scores ≥ upper quartile value, p 
values represent log rank testing of the differences in survival. HR=Hazard Ratio 
(95% CI) 
